© 2024 Corcept Therapeutics, Incorporated
Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.
Posted with permission of the presenter.
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
2024 • Heart in Diabetes 2024
Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)
2024 • ENDO 2024
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
2024 • AACE 2024
MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Difficult-to-Control Diabetes: Is Cortisol at Play?
• 2023 • Roundtable Discussion
Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
Alkhouri et al. • 2023 • AASLD 2023 Congress
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
Donaldson et al. • 2023 • NEALS 22nd Annual Meeting